39.41

0.10% 0.04

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Why IMVT Down? Discussions Forecast

Immunovant Inc stock is traded at $39.41, with a volume of 727.07K. It is up +0.10% in the last 24 hours and up +3.11% over the past month. Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Previous Close:

$39.37

Open:

$39.8

24h Volume:

727.07K

Relative Volume:

0.42

Market Cap:

$8.09B

Revenue:

Net Income/Loss:

$-505.61M

P/E Ratio:

-14.23

EPS:

-2.7697

Net Cash Flow:

$-407.32M

1W Performance:

-2.11%

1M Performance:

+3.11%

6M Performance:

+51.52%

1Y Performance:

+115.12%

1-Day Range:

$38.70

$39.87

1-Week Range:

$38.00

$41.21

52-Week Range:

$14.32

$41.23

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

917-410-3120

Address

1000 PARK FORTY PLAZA, DURHAM, NY

Employee

315

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMVT Immunovant Inc	39.41	8.09B	0	-505.61M	-407.32M	-2.7697
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Mkt Perform
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-14-25	Initiated	Truist	Hold
Jul-10-25	Resumed	Goldman	Neutral
Mar-03-25	Initiated	Jefferies	Hold
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform
Oct-09-24	Reiterated	Oppenheimer	Outperform
Mar-28-24	Initiated	Oppenheimer	Outperform
Mar-13-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	JP Morgan	Overweight
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Jul 24, 2026

Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada

Jul 24, 2026

Immunovant director Atul Pande sells $59,699 in shares - Investing.com

Jul 24, 2026

Form 4 Immunovant Inc For: 24 July By Investing.com - Investing.com Nigeria

Jul 24, 2026

Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com Canada

Jul 24, 2026

Immunovant CFO Tiago Girao sells $263,014 in company stock - Investing.com

Jul 24, 2026

Immunovant CTO Jay Stout sells $110,537 in shares - Investing.com

Jul 24, 2026

Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting - Kalkine Media

Jul 24, 2026

Jul 23, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - The Manila Times

Jul 23, 2026

Jul 22, 2026